Many of these stocks proved resilient during last week's stock market correction, such as GW Pharmaceuticals Inc. (Nasdaq: GWPH), Scotts Miracle-Gro Co. (NYSE: SMG), and Microsoft Corp. (Nasdaq: MSFT).
In fact, the top weed stocks dipped far less than those in more traditional industries.
And their one-day market comeback on Tuesday outpaced anything we saw in autos, retail, or even blue-chip tech.
Days like that remind me of how ridiculous the mid-2017 mainstream media decrees that investors were burned out on pot stocks were. Those folks somehow believed that the excitement was gone and would not return.
So, while the darlings of Wall Street struggled to make back a fraction of their losses, there were significant success stories coming from places like – you guessed it – California's cannabis sector.
The proof points are all right there. This frontier industry keeps making your investment portfolio get fatter and fatter.
I'm looking at thousands of mini catalysts coming your way.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.